Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson diabetes Care Franchise [divested FY2018–FY2019] — International sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, FY2019
0
Period ended Dec 29, 2019
Change on a year earlier
-100.0%
638 in FY2018
History
4 years
Since FY2016
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Diabetes Care Franchise [divested FY2018–FY2019] — International sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2019 | Dec 29, 2019 | 0 | -100.0% | Form 10-K (filed 2020-02-18) ↗ |
| FY2018 | Dec 30, 2018 | 638 | -36.4% | Form 10-K (filed 2021-02-22) ↗ |
| FY2017 | Dec 31, 2017 | 1,003 | -4.5% | Form 10-K (filed 2019-02-20) ↗ |
| FY2016 | Jan 1, 2017 | 1,050 | – | Form 10-K (filed 2019-02-20) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson Diabetes Care Franchise [divested FY2018–FY2019] — International sales ($M) ($M), annual FY2016–FY2019 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/mt_diabetes_legacy_intl
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.